RecruitingPhase 2NCT04881682

Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Sponsor

University of Ulm

Enrollment

20 participants

Start Date

May 1, 2023

Study Type

INTERVENTIONAL

Conditions

CIDP

Summary

This is a randomized controlled study evaluating safety and efficacy of repeated immunoadsorption versus immunoglobulins in steroid-refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Diagnosis of possible, probable, or definite CIDP (typical or atypical) according to European Federation of Neurological Societies (EFNS) guidelines
Disease duration of 3 years or less
Age 18 years or above
Previous treatment with methyl-prednisolone and insufficient therapeutic response as judged by the treating physician, or contraindications against methyl-prednisolone, or clinically significant side effects under methyl-prednisolone therapy as judged by the treating physician

Exclusion Criteria4

Clinical or laboratory evidence of manifest systemic infection, i.e., C-reactive protein (CRP) above 20 mg/l, or evidence of nitrite-positive urinary tract infection
Intake of angiotensin converting enzyme inhibitor within 1 week before first treatment
immunoglobulin A deficiency
Other contraindications against immunoadsorption or intravenous immunoglobulins

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.